The manufacturer stated the effectiveness of the vaccine. The third phase of the vaccine trials began in July and will be completed in mid-November.
The coronavirus vaccine from Pfizer and BioNTech showed more than 90% effectiveness during the trials. This was reported by the press service of the American company on Monday, November 9.
вЂњThe potential candidate for the vaccine showed more than 90% effectiveness in preventing COVID-19 contamination,вЂќ the statement said.
вЂњToday is a beautiful day for science and humanity. The first part of our third phase of COVID-19 vaccine clinical trials provides initial evidence that our drug is capable of preventing coronavirus infection,вЂќ said Albert Burla, COVID-19 Executive Director.
For his part, U.S. President Donald Trump called these results вЂњgreat news.
вЂњStock markets are growing and a vaccine will soon be available. It is reported to be 90% effective. What great news,вЂќ Trump wrote on Twitter.
It should be noted that the third phase of testing started on July 27, 43 thousand people took part in it, almost 40 thousand of whom received the second dose of the potential vaccine so far.
Now the companies will collect information and data on the safety of the vaccine until mid-November, and then all information will be transferred to the U.S. Food and Drug Administration.
If the U.S. regulator approves the vaccine urgently, physicians will be able to receive their first doses by the end of this year.
Recall that earlier Argentina bought 22 million doses of coronavirus vaccine from AstraZeneca. Argentina will receive the vaccine in the first half of 2021 if its trials are completed successfully.
It was also reported that the German vaccine will be ready for the final phase of testing by the end of the year. The interim results of the research are called вЂњvery encouragingвЂќ by scientists. Up to 30 thousand volunteers will take part in the last phase of testing.